Indian Journal of Pharmacy and Pharmacology

Print ISSN: 2393-9079

Online ISSN: 2393-9087

CODEN : IJPPTK

Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award programs. With more...

Article type

Original Article


Article page

94-101


Authors Details

Chandrasekar Leela Priyanka, Balasekar Premkumar*, Calamur Nagarajan Nalini, Mahalakshmi


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 563

PDF Downloaded: 240


Exploring the therapeutic potential of phytoconstituents in treatment of polycystic ovarian syndrome: An study


Original Article

Author Details : Chandrasekar Leela Priyanka, Balasekar Premkumar*, Calamur Nagarajan Nalini, Mahalakshmi

Volume : 10, Issue : 2, Year : 2023

Article Page : 94-101

https://doi.org/10.18231/j.ijpp.2023.020



Suggest article by email

Get Permission

Abstract

Background: Polycystic ovary syndrome (PCOS) is a prevalent condition among women of reproductive age, characterised by hyperinsulinemia, hyperandrogenism, menstrual irregularities, and long-term metabolic disturbances. At present, the conventional approach to managing PCOS involves implementing lifestyle changes, administering pharmacological interventions, and performing surgical procedures. Nevertheless, these therapies do not exhibit promising outcomes for the comprehensive eradication of it. Consequently, natural sources have been regarded as a highly esteemed means of medication and aid in enhancing and regulating PCOS conditions.
Objective: The current study was designed to conduct a screening of various phytoconstituents with a focus on their potential interaction with androgenic targets (1E3G & 2PIV), estrogenic receptors (1U3S), and insulin receptors (3EKK). An assessment was conducted on a compilation of phytoconstituents documented in PCOS with the aim of forecasting drug-like characteristics through an methodology.
Materials and Methods: Thirteen phytoconstituents were selected for the study, namely apigenin, berberine, erdosteine, colchicine, diacerin, mogroside V, naringenin, quercetin, resveratrol, rhamnocitrin, silibinin, tanshinone IIA, and troxerutin. The phytoconstituents were subjected to molecular docking studies using AutoDock Vina to investigate their binding interactions with proposed targets. Additionally, in silico prediction of the toxicity of these phytoconstituents was conducted.
Results: The phytoconstituents that were chosen exhibited favourable pharmacokinetic characteristics for oral bioavailability and drug-likeness, as determined by Lipinski's rule of five. As per the docking results, it was observed that four compounds, namely Apigenin, Tanshinone IIA, Naringenin, and Berberine, exhibited significant binding interactions with the allosteric site residues of the targets.
Conclusion: The identified phytoconstituents that underwent screening exhibit potential as prospective candidates for subsequent development. However, it is imperative to validate the findings through in vitro and in vivo investigations.


Keywords: PCOS, Docking, ADMET, Phytoconstituents, Menstrual, Metabolic


How to cite : Priyanka C L, Premkumar B, Nalini C N, Mahalakshmi, Exploring the therapeutic potential of phytoconstituents in treatment of polycystic ovarian syndrome: An study. Indian J Pharm Pharmacol 2023;10(2):94-101

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.